June 22nd 2022
Experts consider how best to manage adverse events associated with the HER2CLIMB regimen in the setting of HER2+ metastatic breast cancer.
A brief discussion on optimally managing adverse events while treating patients with HER2+ breast cancer.
June 15th 2022
Sara Tolaney, MD, provides practical advice for managing interstitial lung disease in patients with metastatic HER2+ breast cancer.
Shared insight on factors for selecting therapy in a patient with HER2+ metastatic breast cancer progressing through multiple lines of therapy.
June 8th 2022
Expert oncologist Rena Callahan, MD, shares a real-world clinical scenario of a 43-year-old woman with metastatic breast cancer who progressed through multiple lines of therapy.
Expert perspectives on use of trastuzumab deruxtecan in patients with HER2+ breast cancer who develop brain metastases.
June 6th 2022
Shanu Modi, MD, discusses the efficacy findings of the phase 3 DESTINY-Breast04 trial in patients with HER2-low metastatic breast cancer.
June 1st 2022
Centering discussion on a real-world patient profile, subject matter experts discuss use of the HER2CLIMB regimen in HER2+ breast cancer.
Considerations for the role of trastuzumab emtansine in HER2+ breast cancer with the advent of newer HER2-targeted therapies.
May 26th 2022
Shared insight on strategies for managing brain metastases in patients with HER2+ breast cancer.
Shanu Modi, MD, presents the clinical scenario of a 26-year-old woman with triple positive breast cancer.
May 19th 2022
Expert perspectives on the use of trastuzumab deruxtecan in a patient with HER2+ metastatic breast cancer.
Breast medical oncologist, Tiffany Traina, MD, shares a clinical scenario of a patient with HER2+ metastatic breast cancer and discusses her treatment approach in the neoadjuvant, adjuvant, and metastatic settings.